{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"283.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"The half maximal inhibitory concentration (IC50) of INCB054329 was measured. The maximal inhibition of total c-Myc was correlated to the level of drug exposure and demonstrated a high degree of interparticipant variability, parallel to the PK data.\n\nThe measure was performed as a value across all cohorts. The entire dose escalation data set was used to create the relationship curve. Analysis of individual cohorts contained too few subjects and was biased toward one region of the curve so that the relationship was poorly defined.\n\nIndividual data points from all subjects were subjected to a nonlinear least squares regression analysis with no weighting, resulting in a sigmoidal dose response curve defining the relationship. The numerical value given is the projected INCB0054329 concentration in nM that produced 50% inhibition of c-myc expression.","groups":[{"description":"INCB054329 Monotherapy: Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria","id":"OG000","title":"INCB054329 Monotherapy"}],"paramType":"NUMBER","populationDescription":"Individual data points from all subjects were subjected to a nonlinear least squares regression analysis with no weighting, resulting in a sigmoidal dose response curve defining the relationship. The numerical value given is the projected INCB0054329 concentration in nM that produced 50% inhibition of c-myc expression.","reportingStatus":"POSTED","timeFrame":"Day 15 in all cohorts","title":"Pharmacodynamics (PD) Analysis - Total c-Myc % Inhibition Versus INCB054329","type":"SECONDARY","unitOfMeasure":"nM"}